Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Sonobiopsy for Noninvasive and Sensitive Detection of Glioblastoma

NCT: NCT05281731 · RECRUITING

NCT IDNCT05281731
StatusRECRUITING
Start Date2022-04-18
Completion2028-11-30

Brief Summary

This clinical study to evaluate sonobiopsy is significant because sonobiopsy will fundamentally enhance the clinician's insight into the molecular features of an intracranial lesion to tailor treatment approaches and optimize outcomes. In addition to the standard diagnostics of anatomic imaging and surgical histology, sonobiopsy has the potential to become the third pillar for brain tumor management by radically advancing the ability to easily and regularly acquire tumor genetic and molecular signatures. This enhanced capability will have a dramatic impact on patient survival and quality of life.

Frequently Asked Questions

What is Sonobiopsy for Noninvasive and Sensitive Detection of Glioblastoma?

Sonobiopsy for Noninvasive and Sensitive Detection of Glioblastoma is a clinical trial registered under NCT05281731. Current status: RECRUITING.

What is the status of NCT05281731?

The current status of NCT05281731 (Sonobiopsy for Noninvasive and Sensitive Detection of Glioblastoma) is: RECRUITING.

When did Sonobiopsy for Noninvasive and Sensitive Detection of Glioblastoma start?

Sonobiopsy for Noninvasive and Sensitive Detection of Glioblastoma started on 2022-04-18.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.